Fredun制药公司通过Infomerics将其升级为BBB+, 称其业绩和增长强劲,提升了其全球扩张前景。 Fredun Pharmaceuticals upgraded to BBB+ by Infomerics, citing strong performance and growth, boosting its global expansion prospects.

Fredun Pharmaceuticals Limited 因其银行贷款额为156.17亿卢比，获得了Infomerics的BBB+长期信用评级，较BBB上调，前景稳定，体现了强劲的财务表现、严谨的资本管理以及2024财年和25财年的持续增长。 Fredun Pharmaceuticals Limited has received a BBB+ long-term credit rating from Infomerics, up from BBB with a stable outlook, for its ₹156.17 crore bank facilities, reflecting strong financial performance, disciplined capital management, and consistent growth in FY24 and FY25. 这一升级除保持A2的短期评级外,还提高了公司的信誉和财政灵活性,支持非洲、东南亚、独联体国家和拉丁美洲的扩展。 The upgrade, alongside a maintained A2 short-term rating, enhances the company’s credibility and financial flexibility, supporting expansion in Africa, Southeast Asia, CIS nations, and Latin America. 这一变动紧随Brickwork的类似评级提升，凸显了对Fredun持续表现和全球竞争力的信心。 The change follows a similar rating boost from Brickwork and underscores confidence in Fredun’s sustained performance and global competitiveness.